Physician profile
Mackenzie Sweeney
NPI 1558095737
$2,518.03
in general payments reported to CMS, 2019-2025
11 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $473 · 2023: $1,349 · 2024: $498 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,044.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $906.54 | 2022-2024 | Mounjaro, Jardiance, Lyumjev |
| Novo Nordisk INC | $458.84 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $325.55 | 2022-2024 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $304.95 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $174.47 | 2023-2024 | Evenity, Prolia |
| Insulet Corporation | $100.19 | 2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $66.96 | 2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $58.56 | 2023 | Farxiga |
| Abbvie INC. | $44.95 | 2023 | |
| Medtronic, INC. | $40.47 | 2023-2024 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.55 | 2023 | Synjardy, Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.